Brian Baldari Email & Phone Number

Brick, Nj, Us

Brick, Nj, Us

Raleigh, North Carolina, United States

● Developed and executed strategic plans for 7 in-market brands and 25+ pipeline assets, supporting 14% year on year franchise growth across 10 therapeutic areas● Led cross-functional governance team (Marketing, Medical, Market Access, R&D, Supply Chain) through 9-stage PLM process, ensuring timely development, registration, and launch of products while mitigating risks and maximizing ROI● Championed product lifecycle optimization efforts, balancing new product introductions with strategic discontinuations to drive sustainable growth and maintain market leadership● Conducted comprehensive assessments of 20+ BD&L and external partnership opportunities, identifying synergies to enhance internal portfolio and drive long-term growth strategies● Directed competitive intelligence and market research initiatives to inform data-driven decision-making and forecasting, ensuring a differentiated and customer-centric product pipeline

Princeton, New Jersey, United States

• Orchestrated and implemented strategic product and marketing initiatives for the nephrology and rare disease portfolio

East Hanover, New Jersey, United States

• Spearheaded the creation and execution of integrated product and portfolio strategies for the rare renal therapeutic area, advancing revolutionary brands, including Fabhalta (iptacopan), atrasentan, zigakibart, and the entire pipeline.• Recognized with the esteemed President’s Award, an exclusive honor reserved for the top 5 leaders in the US.

East Hanover, New Jersey, United States

• Successfully built iptacopan from the ground up, leading inception, development, and launch preparation to fortify competitive positioning, boost revenue growth, and drive brand recognition and reputation. • Shaped product strategy for 10 indications (PNH, C3G, IgAN, IC-MPGN, LN, MN, gMG, IgAV, AAV, CAD), establishing cohesive brand messaging to ensure customer understanding and engagement.• Developed a high-caliber marketing team by acquiring talent strategically, planning for succession, and fostering associate growth.

East Hanover, Nj

• Spearheaded global strategic marketing for the WetAMD indication launch in China and emerging markets and crafted the global commercial strategy for all Lifecycle Management (LCM) indications such as DME, RVO, and PDR. • Developed annual global P&L and operating plans, including financial forecasts, NPVs, KPI’s, M&S expense forecasts, scenario planning, and sensitivityanalyses.• Recognized for industry excellence, earning the Global Culture Award for global emerging market strategy for the launch of Beovu.

Greater New York City Area

• Secured approval for Full Development Plan (FDP) of pelacarsen for reducing lipoprotein(a) levels, while leading the promotional strategy for cardiovascular pipeline molecules in late-stage research.• Led the Business Development & Licensing (BD&L) acquisition of pelacarsen (IONIS-APO(a)-LRx) from Ionis Pharmaceuticals, while successfully divesting abelacimab (MAA868) to Anthos Therapeutics • Partnered with BD&L to identify, screen, and evaluate 30+ potential in-licensing opportunities to expand the company’s product portfolio and market presence.

Jersey City, Nj

• Took ownership of Esmya brand launch with minimal prior development, conceptualizing and implementing the marketing plan for launch in uterine fibroids in under 12 months. • Orchestrated a Women’s Health Key Opinion Leader engagement plan, forging strong relationships with 30+ industry leaders to advance knowledge and share insights to support product development and customer needs. • Directed 3 professionals and managed a $65M budget, demonstrating superior leadership abilities and notable financial acumen.

Ridgefield, Connecticut, United States

• Championed Managed Markets Marketing team that executed strategies across 7 diabetes brands with Payor and Health System customers.• Established pioneering Payor and Health System Marketing role at Boehringer, including team building, strategic planning, and direction.• Formulated Boehringer’s Health Systems Value proposition and initiated Customer Solutions Steering Committee to evaluate strategic customer partnerships, as well as facilitated 13 collaborations in its first year, including key partnerships with Kaiser and Geisinger.• Supervised a team of 4, effectively managed a $9M budget, and achieved $1.1B in sales for the Tradjenta/Jentadueto diabetes portfolio.

Ridgefield, Ct

● Led pipeline business strategy across all phases of development for Obesity, Cardiovascular, and Metabolic therapeutic areas including 60+ compounds across 8 indications (ASCVD, diabetes, obesity, chronic kidney disease, retinopathy, etc.)● Drove global disease area strategy (DAS) for obesity and managing commercial strategies for several obesity compounds including BI473494 (LAAMA), BI456906 (GLP1/GCGR Agonist), and BI1322645 (GOAT Inh.).● Led BD&L acquisition of VAP1 inhibitor from Pharmaxis (PXS-4728) in NASH and provided commercial analysis for 200+ product candidates.● Won Lead and Learn Marketing Excellence Award for collaboration; the Marketing Rock Star Award for leadership; and the Top Performer Award for top marketer across the organization of 100+ peers.

Ridgefield, Ct

• Grew Tradjenta's market share 185% through improved sales materials and execution, overcoming slow launch uptake among prescribers.

Launched 2 new products (Tradjenta and Jentadueto) in the HCP portfolio with ownership of omnichannel promotion including digital and media strategy and implementation.

Led a team of 2 Regional Managers (leader of leaders) and 18 MSLs in Female Sexual Dysfunction for the launch of Addyi.

New York City Metropolitan Area

Morristown, New Jersey, United States

Formerly Watson Pharmaceuticals

Master Of Business Administration - Mba, Mba In Healthcare

Doctor Of Pharmacy (Pharmd), Pharmacy

Bachelors Of Science (Bs), Pharmacy (Rph)